NCT06491472View on ClinicalTrials.gov

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

July 15, 2026

Study Completion Date

July 15, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Ivonescimab

20mg/kg,IV,d1,Q3W

DRUG

Gemcitabine

1000mg/m2, IV, d1/8, Q3W

DRUG

Nab paclitaxel

125mg/m2, IV, d1/8, Q3W

RADIATION

SBRT

5Gy \*5 F

Trial Locations (1)

Unknown

RECRUITING

Wuhan Union Hospital of China, Wuhan

Sponsors

Collaborators (1)

Akesobio
All Listed Sponsors
collaborator

Akesobio

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER